- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07948577
Henagliflozin on Myocardial Fibrosis in Obese Patients (LY2026-317-C)
Effect of Henagliflozin on Myocardial Fibrosis in Obese Patients: A Prospective, Randomized, Controlled Study.
This study evaluates the anti-fibrotic efficacy and safety of henagliflozin versus metformin in non-diabetic obese patients with subclinical myocardial fibrosis, explores whether the benefit is mediated by metabolic improvement or direct myocardial protection, and aims to provide high-level evidence for early pharmacological intervention.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This study will be based on an established specialized cohort of non-diabetic patients with simple obesity and a multi-omics database. By integrating clinical data with multidimensional information including genomics, metabolomics, and proteomics, patients at high risk of myocardial fibrosis will be identified. After myocardial fibrotic changes are further confirmed by CMR, eligible participants will be randomly assigned to the control group (metformin) or the intervention group (henagliflozin). The treatment period will be 24 weeks, followed by a 24-week safety follow-up period. The difference in the change in the degree of myocardial fibrosis before and after treatment between the two groups will be compared to determine the efficacy of henagliflozin in counteracting myocardial fibrosis in the non-diabetic obese population. This project aims to provide high-level evidence-based medical evidence for targeted pharmacological intervention of obesity-related early cardiac damage, with the goal of improving the long-term prognosis of this population.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Jing Ma
- Telefonnummer: 021-68383420
- E-Mail: majing3436@163.com
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- BMI ≥ 28 kg/m², or waist circumference ≥ 90 cm in men or ≥ 85 cm in women, or body fat percentage ≥ 25% in men or ≥ 30% in women;
- Adults aged 18 to 65 years;
- ECV greater than 30%;
- No participation in other clinical trials within the past three months.
Exclusion Criteria:
- Diagnosed with diabetes mellitus or prediabetes;
- History of coronary artery disease (coronary stenosis > 50% on coronary angiography or coronary computed tomography), history of myocardial infarction, history of coronary artery bypass grafting or percutaneous coronary intervention; non-ischemic cardiovascular diseases such as idiopathic cardiomyopathy, valvular disease, congenital heart disease, or cor pulmonale; arrhythmia or bundle branch block on electrocardiogram; implantation of a cardiac pacemaker or defibrillator;
- Uncontrolled hypertension: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg during the screening visit (mean of three blood pressure measurements in the supine position);
- Symptomatic hypotension and/or systolic blood pressure < 90 mmHg at V1 or V2, or patients judged by the clinician to have hypovolemia;
- Use within 3 months of: 1) medications that may affect body weight or glucose metabolism, including systemic glucocorticoids (excluding topical, ophthalmic, nasal spray, or inhaled preparations; excluding low-dose or overnight dexamethasone suppression test use), growth hormone, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic/tetracyclic antipsychotic drugs, other psychiatric medications or sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts), etc.; 2) traditional Chinese medicines, Chinese patent medicines, herbal medicines, health supplements, meal replacements, etc., with weight-loss or glucose-lowering effects; 3) use of or current use of the following weight-loss drugs or drugs containing the following ingredients, such as: sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, clobenzorex, fenfluramine, amfepramone, lorcaserin, phentermine/topiramate combination, naltrexone/bupropion combination, etc.; 4) use of glucose-lowering drugs, such as metformin, α-glucosidase inhibitors, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones (TZDs), insulin, etc.;
- Other endocrine and metabolic diseases such as hyperthyroidism, hypothyroidism, acromegaly, diabetes insipidus, or Cushing's syndrome;
- Concurrent malignant tumors;
- Severe liver disease (Child-Pugh class C) or liver enzymes (ALT/AST) > 3 times the upper limit of normal;
- Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m²;
- Cognitive impairment, or concomitant infectious or autoimmune diseases;
- History of recurrent urinary or reproductive tract infections;
- Patients who refuse henagliflozin or metformin treatment, or who are allergic to henagliflozin, metformin, or their excipients; those with incomplete questionnaires or incomplete data;
- Pregnant or breastfeeding women.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Interventionsgruppe
|
Oral henagliflozin 10 mg once daily for 24 weeks, administered at a fixed dose without adjustment. Used in non-diabetic obese patients with subclinical myocardial fibrosis as an off-label investigational treatment. |
|
Aktiver Komparator: Control Group
oral metformin tablets 2000 mg/day; or the maximum tolerated dose (≥1000 mg/day). |
Oral metformin titrated to 2000 mg/day (1000 mg twice daily), or the maximum tolerated dose (≥1000 mg/day), for 24 weeks. Dose titration: 500 mg twice daily for weeks 1-2, then 1000 mg twice daily from week 3 if tolerated. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from Baseline in Myocardial Extracellular Volume (ECV) Fraction at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Change from baseline in myocardial extracellular volume (ECV) fraction, as measured by cardiac magnetic resonance (CMR) T1 mapping pre- and post-contrast. ECV is calculated from pre- and post-contrast T1 relaxation times and the patient's hematocrit. The between-group difference in ΔECV (Henagliflozin vs. Metformin) will be compared; continuous data will be summarized as mean ± SD and analyzed using mixed-effects models. |
Baseline to Week 24
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Change from Baseline in Epicardial Adipose Tissue (EAT) Volume at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Cardiac Output at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Heart Rate at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Peak Filling Rate at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Stroke Volume Index (BSA-corrected) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in End-Systolic Volume Index (BSA-corrected) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in End-Diastolic Volume Index (BSA-corrected) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Left Ventricular Mass Index (BSA-corrected) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Early-to-Late Filling Ratio (E/A) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in LV Mass to End-Diastolic Volume Ratio (MVR) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Cardiac Index at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Body Weight at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Body Mass Index (BMI) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Systolic Blood Pressure at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Diastolic Blood Pressure at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Glycated Hemoglobin (HbA1c) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Fasting Plasma Glucose at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in HOMA-IR (Insulin Resistance Index) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Total Cholesterol at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Triglycerides at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in High-sensitivity CRP (hsCRP) at 24 Weeks
Zeitfenster: Baseline to Week 24
|
Baseline to Week 24
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Zeitfenster: Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Genitourinary Tract Infections
Zeitfenster: Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Gastrointestinal Adverse Events
Zeitfenster: Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Ketoacidosis
Zeitfenster: Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Serious Adverse Events (SAEs)
Zeitfenster: Up to 48 Weeks
|
Up to 48 Weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Jing Ma, Department of Endocrinology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- LY2026-317-C
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .